HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Goldstein, I. Articles by Taylor, T. Search for Related Content PubMed PubMed Citation Articles by Goldstein, I. Articles by Taylor, T. Social Bookmarking                What's this?

Vardenafil, a New Phosphodiesterase Type 5 Inhibitor, in the Treatment of Erectile Dysfunction in Men With Diabetes

A multicenter double-blind placebo-controlled fixed-dose study

¹ Boston University Medical Center, Boston, Massachusetts
² South Coast Urological Medical Center, Laguna Hills, California
³ Diabetes and Glandular Disorders Clinic, San Antonio, Texas
⁴ Bayer Corporation, West Haven, Connecticut

OBJECTIVE—This study evaluated the efficacy and safety of vardenafil treatment for erectile dysfunction (ED) in men with diabetes.

RESEARCH DESIGN AND METHODS—In this prospective multicenter double-blind placebo-controlled fixed-dose parallel-group phase III trial, 452 patients with diabetes (type 1 or type 2) and ED were randomized to take 10 or 20 mg vardenafil or placebo as needed for 12 weeks. Efficacy responses were assessed by International Index of Erectile Function domain scores, rates of vaginal penetration and successful intercourse, and a global assessment question (GAQ) about erection improvement during the previous 4 weeks.

RESULTS—After 12 weeks of treatment, a dose-dependent (P = 0.02) improvement in erections was noted for the GAQ, with 57 and 72% of men taking 10 mg or 20 mg vardenafil, respectively, reporting improved erections, in contrast to 13% after taking placebo (P < 0.0001). For the erectile function domain, dose-dependent (P = 0.03) final scores for the 10- and 20-mg dose were 17.1 and 19.0 compared with 12.6 for placebo (P < 0.0001). Both vardenafil doses significantly enhanced the rates of successful penetration (P < 0.0001) and successful intercourse (P < 0.0001) compared with placebo. Vardenafil treatment was effective in increasing intercourse success rates at all levels of baseline ED severity, at each level of plasma HbA_1c, and for type 1 and 2 diabetes. Treatment-emergent adverse events were primarily mild to moderate headache (13%), flushing (10%), and rhinitis (10%).

CONCLUSIONS—Vardenafil statistically improved erectile function and was generally well tolerated in these diabetic patients with ED.

Abbreviations: ECG, electrocardiogram • ED, erectile dysfunction • EF, erectile function • GAQ, global assessment question • IIEF, International Index of Erectile Function • LOCF, last observation carried forward • PDE5, phosphodiesterase type 5

CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				F. Giuliano, E. Rubio-Aurioles, M. Kennelly, F. Montorsi, E. D. Kim, A. E. Finkbeiner, P. J. Pommerville, M. W. Colopy, H. J. Wilkins, B. H. Wachs, et al. Efficacy and safety of vardenafil in men with erectile dysfunction caused by spinal cord injury Neurology, January 24, 2006; 66(2): 210 - 216. [Abstract] [Full Text] [PDF]

				W. J. G. Hellstrom, M. Elhilali, M. Homering, T. Taylor, and M. Gittleman Vardenafil in Patients With Erectile Dysfunction: Achieving Treatment Optimization J Androl, September 1, 2005; 26(5): 604 - 609. [Abstract] [Full Text] [PDF]

				S. M Setter, J. L Iltz, J. E Fincham, R K. Campbell, and D. E Baker Phosphodiesterase 5 Inhibitors for Erectile Dysfunction Ann. Pharmacother., July 1, 2005; 39(7): 1286 - 1295. [Abstract] [Full Text] [PDF]

				A. J.M. Boulton, A. I. Vinik, J. C. Arezzo, V. Bril, E. L. Feldman, R. Freeman, R. A. Malik, R. E. Maser, J. M. Sosenko, and D. Ziegler Diabetic Neuropathies: A statement by the American Diabetes Association Diabetes Care, April 1, 2005; 28(4): 956 - 962. [Full Text] [PDF]

				J. S. Brown, H. Wessells, M. B. Chancellor, S. S. Howards, W. E. Stamm, A. E. Stapleton, W. D. Steers, S. K. Van Den Eeden, and K. T. McVary Urologic Complications of Diabetes Diabetes Care, January 1, 2005; 28(1): 177 - 185. [Full Text] [PDF]

				D. F. Penson and H. Wessells Erectile Dysfunction in Diabetic Patients Diabetes Spectr, October 1, 2004; 17(4): 225 - 230. [Abstract] [Full Text] [PDF]

				L. De Young, D. Yu, R. M. Bateman, and G. B. Brock Oxidative Stress and Antioxidant Therapy: Their Impact in Diabetes-Associated Erectile Dysfunction J Androl, September 1, 2004; 25(5): 830 - 836. [Abstract] [Full Text] [PDF]

				D. A. Norwood, N. E. Eraikhuemen, M. Larose-Pierre, E. Branch III, and R. M. Norwood Advances in the Treatment of Erectile Dysfunction: A Focus on Tadalafil Journal of Pharmacy Practice, August 1, 2004; 17(4): 239 - 250. [Abstract] [PDF]

				New oral drugs for erectile dysfunction DTB, July 1, 2004; 42(7): 49 - 52. [Abstract] [Full Text] [PDF]

				L. Fazio and G. Brock Erectile dysfunction: management update Can. Med. Assoc. J., April 27, 2004; 170(9): 1429 - 1437. [Abstract] [Full Text] [PDF]

				D. O. Sussman Pharmacokinetics, Pharmacodynamics, and Efficacy of Phosphodiesterase Type 5 Inhibitors J Am Osteopath Assoc, March 1, 2004; 104(3_suppl): 11S - 15S. [Abstract] [Full Text]